Search clinical trials for: Canagliflozin

Total 665 results

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions

Healthy Subjects

Canada
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions

Healthy Subjects

Canada
Fundación Pública Andaluza para la Investigación...

Unknown

SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease

Type 2 Diabetes Mellitus

Spain
AstraZeneca
Bristol-Myers Squibb

Completed

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

Type 2 Diabetes

Australia, United States, Canada, Mexico, Puerto Rico, Germany, Hungary, Ireland, Poland, Romania, Denmark, Czech Republic, India, Colombia, Finland, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Bioequivalence

United States
National Taiwan University Hospital

Recruiting

SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning

Ventilator Lung | Heart Failure Acute

Taiwan
Sohag University

Not yet recruiting

The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus

Fatty Liver, Nonalcoholic
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

Diabetes Mellitus, Type 2

United States
Oman Ministry of Health

Not yet recruiting

The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes (DAPA-ANDO)

Obesity | Weight Loss | Effect of Drug | Dapagliflozin Adverse Reaction
University of Edinburgh
AstraZeneca; NHS Lothian

Recruiting

The DAPA-MEMRI Trial (DAPA-MEMRI)

Heart Failure | Diabetic Cardiomyopathies

United Kingdom
M.H.H. Kramer
AstraZeneca

Completed

Renoprotective Effects of Dapagliflozin in Type 2 Diabetes (RED)

Diabetes Mellitus, Type 2 | Diabetic Nephropathies

Netherlands
LG Chem

Unknown

A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone

Diabetes Mellitus, Type 2
LM Diagnósticos S.L.
AstraZeneca

Unknown

Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes

Type2 Diabetes

Spain
AstraZeneca
AstraZeneca, Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Type 2 Diabetes

China, Korea, Republic of, India
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Sheba Medical Center

Unknown

Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease

Coronary Disease With Diabetes Mellitus

Israel
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
Sihuan Pharmaceutical Holdings Group Ltd.

Unknown

Janagliflozin Treat Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Metformin

Diabetes Mellitus, Type 2

China
University of Palermo
AstraZeneca; University of Catania

Unknown

Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes

Type 2 Diabetes Mellitus

Italy
AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects

Diabetes Mellitus, Type 2

Argentina
Washington University School of Medicine
Juvenile Diabetes Research Foundation

Recruiting

Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency

Diabetes Mellitus, Type 1

United States
Yooyoung Pharmaceutical Co., Ltd.

Active, not recruiting

Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

Type 2 Diabetes

Korea, Republic of
AstraZeneca
Biocard

Completed

An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions

Diabetes Mellitus, Type 2

Russian Federation
University Health Network, Toronto

Recruiting

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients (HALLMARK)

Kidney Transplant Recipients

Canada
Hilda Elizabeth Macías Cervantes

Completed

Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography

Myocardial Infarction | Diabetes Mellitus, Type 2 | Unstable Angina | Diabete Type 2

Mexico
Shanghai Zhongshan Hospital

Active, not recruiting

Remission of Type 2 Diabetes With Dapagliflozin (READ Trial) (READ)

Type 2 Diabetes

China
Dong-A ST Co., Ltd.

Completed

Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Type 2 Diabetes

Korea, Republic of
Weill Medical College of Cornell University

Withdrawn

Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes (Dexlar)

Diabetes Mellitus, Type 2

United States
Sequana Medical N.V.

Recruiting

Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0 (MOJAVE)

Heart Failure | Volume Overload

United States
AstraZeneca
Astra Zeneca, Bristol-Myers Squibb

Completed

Add-on to Thiazolidinedione (TZD) Failures

Type 2 Diabetes

Taiwan, United States, Argentina, Canada, Mexico, Puerto Rico, Philippines, India, Peru
Centro Universitario de Ciencias de la Salud, Mexico

Active, not recruiting

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Diabetes Mellitus Type 2 Without Complication

Mexico
Lexicon Pharmaceuticals

Completed

Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Healthy Subjects

United States
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE)

Diabetes Mellitus, Type 2 | Diabetic Nephropathy

United States, Canada, France, Germany, Poland, Ukraine, United Kingdom, China, Taiwan, Spain, Argentina, Colombia, Mexico, Bulgaria, India, Malaysia, Romania, Serbia, South Africa, Japan, Australia, Korea, Republic of, Chile, New Zealand and more
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function

Hepatic Insufficiency | Healthy

United States
University of Campinas, Brazil
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects

Hypertension | Obesity | Diabetes Mellitus, Type 2 | Blood Pressure | Vascular Stiffness | Cardiac Hypertrophy | Microalbuminuria

Brazil
Kiyuk Chang
Seoul St. Mary's Hospital; Pusan National University Hospital; Korea University... and other collaborators

Recruiting

SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients With Acute Myocardial Infarction, a Prospective, Multi-center Registry Study (RECORD-AMI)

Myocardial Infarction | Diabetes Mellitus, Type 2

Korea, Republic of
University Hospital, Rouen
AstraZeneca

Not yet recruiting

Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC) (DAPAVASC)

Renal Insufficiency, Chronic

France
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers

Healthy
University of California, San Diego
Juvenile Diabetes Research Foundation; The Leona M. and Harry B. Helmsley Charitable... and other collaborators

Completed

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

Type 1 Diabetes

United States
Sequana Medical N.V.

Active, not recruiting

Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion (SAHARA)

Heart Failure | Volume Overload

Georgia
Janssen Research & Development, LLC

Completed

An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin (COMETA)

Diabetes Mellitus, Type 2

Mexico
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

Healthy

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Healthy Volunteers

United States
University of Pisa

Completed

Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.

Type2 Diabetes Mellitus

Italy
Clinical Research Centre, Malaysia
University of Malaya; Ministry of Health, Malaysia

Recruiting

The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD) (EpiCAD)

Coronary Artery Disease

Malaysia
Dong-A ST Co., Ltd.

Completed

Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Type2 Diabetes

Korea, Republic of
Vanderbilt University Medical Center
AstraZeneca

Completed

Efficacy and Safety of Dapagliflozin in Acute Heart Failure (DICTATE-AHF)

Heart Failure | Diabetes Mellitus, Type 2

United States
Damanhour University

Recruiting

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Heart Failure | Reduced Ejection Fraction Heart Failure

Egypt

3

Subscribe